Home Ingredients K2Quest® (Fermentation-Derived Vitamin K2 MK-7)
Bone HealthCardiovascularWomen's Health

K2Quest® (Fermentation-Derived Vitamin K2 MK-7)

Evidence Level
Strong
1 Clinical Trial
3 Documented Benefits
4/5 Evidence Score

K2Quest® (NutriScience Innovations) is a high-purity Vitamin K2 as menaquinone-7 (MK-7) produced through microbial fermentation — the long-chain form of K2 with the longest plasma half-life (~3 days vs. ~1 hour for MK-4) and highest bioavailability among all K2 forms. Vitamin K2 MK-7 activates both osteocalcin (directing calcium into bones) and matrix Gla protein (preventing calcium from depositing in arteries) — making it the critical link between calcium supplementation, bone density, and cardiovascular safety. K2Quest® also supports PMS symptom management through progesterone modulation.

Studied Dose 90–180 mcg/day MK-7 for bone and cardiovascular health; PMS: 90 mcg/day; 3-year RCT dose: 180 mcg/day; fermentation-derived MK-7 has ~72-hour plasma half-life enabling once-daily dosing
Active Compound Menaquinone-7 (MK-7) — K2Quest® by NutriScience Innovations; fermentation-derived Vitamin K2 in the all-trans configuration; typical dose 90–360 mcg/day

Benefits

Bone density and fracture risk reduction

Vitamin K2 MK-7 activates osteocalcin — the protein that binds calcium and incorporates it into hydroxyapatite crystal in bone matrix. Without adequate K2, supplemental calcium circulates unbound and deposits in arteries rather than bones. A 3-year double-blind RCT confirmed MK-7 (180 mcg/day) significantly improved bone mineral density and bone strength markers vs. placebo in postmenopausal women, with the longest placebo-controlled bone study published for a K2 supplement.

Supported by Trial 1

Cardiovascular protection — preventing arterial calcification

Matrix Gla protein (MGP) is the body's primary inhibitor of vascular calcification — but it requires Vitamin K2 to become activated (carboxylated). Inadequate K2 leaves MGP inactive, allowing calcium to deposit in arterial walls, increasing arterial stiffness and cardiovascular risk. Clinical studies confirm MK-7 supplementation significantly reduces circulating inactive-MGP (a marker of arterial calcification risk) and improves arterial stiffness in adults.

Supported by Trial 1

PMS symptom management

Clinical research on MK-7 demonstrates reduction in PMS-associated symptoms including mood changes, cramps, and bloating — attributed to K2's role in progesterone receptor activation and modulation of prostaglandin pathways that drive menstrual cramping. This positions K2Quest® for women's health formulations combining bone, cardiovascular, and hormonal benefits.

Supported by Trial 1

Mechanism of action

1

Carboxylation of Gla-proteins: osteocalcin and MGP activation

Vitamin K2 serves as the essential cofactor for gamma-glutamyl carboxylase — the enzyme that carboxylates (activates) Gla-domain proteins including osteocalcin and matrix Gla protein (MGP). Carboxylated osteocalcin binds hydroxyapatite (bone mineral) and calcium ions, anchoring them in bone matrix for density and strength. Carboxylated MGP actively chelates calcium ions in vessel walls and inhibits vascular smooth muscle calcification. Without adequate K2, both proteins remain inactive (undercarboxylated), resulting in bone loss and arterial calcification — explaining the strong epidemiological association between K2 intake and both bone and cardiovascular health.

Clinical trials

1
MK-7 Vitamin K2 for Bone Mineral Density — 3-Year RCT

Randomized, double-blind, placebo-controlled trial of MK-7 (180 µg/day) vs placebo in 244 healthy postmenopausal women over 3 years. Outcomes: bone mineral density (DXA at lumbar spine, femoral neck, hip), bone strength markers, vertebral fracture risk. (Knapen et al. 2013, Osteoporos Int)

244 healthy postmenopausal women. 3-year intervention.

MK-7 significantly preserved bone mineral density at lumbar spine (BMD +0.7%) and femoral neck vs placebo (which showed BMD decline of -1.3%). Bone strength markers (osteocalcin carboxylation status) improved. Critical context: this trial is the foundation of MK-7 bone health marketing. Pharmaceutical bisphosphonates (alendronate, zoledronate) and denosumab produce larger BMD increases (~3-7% over 3 years) and have direct fracture reduction evidence. MK-7 is a reasonable adjunctive bone health intervention for healthy postmenopausal women, not a substitute for established osteoporosis pharmacotherapy.

Side effects and drug interactions

Common Potential side effects

Excellent safety profile at 90–360 mcg/day
Well-tolerated in all clinical studies including the 3-year RCT
No upper tolerable intake level established by most regulatory agencies

Important Drug interactions

Warfarin (vitamin K antagonist) — MK-7 directly opposes warfarin's mechanism; avoid if on warfarin therapy
Other anticoagulants — maintain consistent K2 intake and monitor clotting parameters
Broad-spectrum antibiotics — reduce intestinal K2 production; may need to increase supplemental K2

Featured in these supplement guides

Bone Density→Mouth & Gum Health→

More Bone Health Ingredients

Bone Health
Calcium
Calcium is the most abundant mineral in the body — about 99% stored in bones and teeth, wi…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Muscle & Recovery
Magnesium
Magnesium is the fourth most abundant mineral in the body and a cofactor for over 300 enzy…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…

Frequently asked questions about K2Quest® (Fermentation-Derived Vitamin K2 MK-7)

What is K2Quest?

K2Quest® (NutriScience Innovations) is a high-purity Vitamin K2 as menaquinone-7 (MK-7) produced through microbial fermentation — the long-chain form of K2 with the longest plasma half-life (~3 days vs. ~1 hour for MK-4) and highest bioavailability among all K2 forms.

What is K2Quest used for?

K2Quest is researched primarily for Bone Health, Cardiovascular, and Women's Health. Vitamin K2 MK-7 activates osteocalcin — the protein that binds calcium and incorporates it into hydroxyapatite crystal in bone matrix. Without adequate K2, supplemental calcium circulates unbound and deposits in arteries rather than bones.

What is the recommended dosage of K2Quest?

The clinically studied dose is 90–180 mcg/day MK-7 for bone and cardiovascular health; PMS: 90 mcg/day; 3-year RCT dose: 180 mcg/day; fermentation-derived MK-7 has ~72-hour plasma half-life enabling once-daily dosing Always follow the product label and check with a healthcare provider for personal advice.

Is K2Quest safe, and does it have side effects?

For most healthy adults, K2Quest is well tolerated at studied doses. Reported effects can include: Excellent safety profile at 90–360 mcg/day Well-tolerated in all clinical studies including the 3-year RCT It may also interact with some medications. K2Quest is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does K2Quest interact with any medications?

Possible interactions include: Warfarin (vitamin K antagonist) — MK-7 directly opposes warfarin's mechanism; avoid if on warfarin therapy Other anticoagulants — maintain consistent K2 intake and monitor clotting parameters If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for K2Quest?

NutraSmarts rates the evidence for K2Quest as Strong (4 out of 5). It is backed by 1 clinical trial and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Ronn SH, Harslof T, Oei L, Pedersen SB, Langdahl BL The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial Osteoporosis International. 2021;32(1):185-191. doi: 10.1007/s00198-020-05638-z.PubMedUsed to support: Backs the bone-mineral-density topic for MK-7 with honest mixed results: a 3-year RCT in postmenopausal women with osteopenia where MK-7 did not significantly improve BMD or microarchitecture vs placebo at the primary endpoints. Generic MK-7, not K2Quest-specific; illustrates the mixed large-trial evidence.
  2. Zhang Y, Liu Z, Duan L, Ji Y, Yang S, Zhang Y, Li H, Wang Y, Wang P, Chen J, Li Y Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study Calcified Tissue International. 2020;106(5):476-485. doi: 10.1007/s00223-020-00669-4.PubMedUsed to support: Backs the bone-density claim: 1 year of low-dose MK-7 helped maintain/improve lumbar-spine BMD vs control in middle-aged and elderly adults. Honest limits: modest effect, open-label control design, and generic MK-7 (not K2Quest); consistent with promising-but-mixed MK-7 bone evidence.
  3. Caluwe R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study Nephrology Dialysis Transplantation. 2014;29(7):1385-90. doi: 10.1093/ndt/gft464.PubMedUsed to support: Backs the vascular/arterial mechanism: MK-7 dose-dependently activated matrix Gla protein (the vitamin-K-dependent inhibitor of arterial calcification) in hemodialysis patients. Honest limits: a short dose-finding study in a high-risk dialysis population using a biomarker (dephospho-uncarboxylated MGP) rather than a hard cardiovascular outcome; generic MK-7.
  4. Naiyarakseree N, Phannajit J, Naiyarakseree W, Mahatanan N, Asavapujanamanee P, Lekhyananda S, Vanichakarn S, Avihingsanon Y, Praditpornsilpa K, Eiam-Ong S, et al. Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial Nutrients. 2023;15(11):2422. doi: 10.3390/nu15112422.PubMedUsed to support: Backs the arterial-stiffness claim with honest mixed results: an MK-7 RCT measuring carotid-femoral pulse-wave velocity where MK-7 did not significantly reduce arterial stiffness overall (benefit only in a diabetic subgroup) in a high-risk dialysis population; generic MK-7, not K2Quest-specific.